Paul Rivard - Net Worth and Insider Trading
Paul Rivard Net Worth
The estimated net worth of Paul Rivard is at least $16,666 dollars as of 2024-11-13. Paul Rivard is the Chief Legal Officer of TNF Pharmaceuticals Inc and owns about 13,333 shares of TNF Pharmaceuticals Inc (TNFA) stock worth over $16,666. Details can be seen in Paul Rivard's Latest Holdings Summary section.
Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the final shares held after open market or private purchases and sales of common stock with a transaction code of "P" or "S" on Form 4, assuming that Paul Rivard has not made any transactions after 2023-08-24 and currently still holds the listed stock(s). Please note that this estimate may not reflect the actual net worth.
Transaction Summary of Paul Rivard
Paul Rivard Insider Ownership Reports
Based on ownership reports from SEC filings, as the reporting owner, Paul Rivard owns 1 companies in total, including TNF Pharmaceuticals Inc (TNFA) .
Click here to see the complete history of Paul Rivard’s form 4 insider trades.
Insider Ownership Summary of Paul Rivard
Ticker | Comapny | Transaction Date | Type of Owner |
---|---|---|---|
TNFA | TNF Pharmaceuticals Inc | 2023-08-24 | EVP of Operations & GC |
Paul Rivard Latest Holdings Summary
Paul Rivard currently owns a total of 1 stock. Paul Rivard owns 13,333 shares of TNF Pharmaceuticals Inc (TNFA) as of August 24, 2023, with a value of $16,666.
Latest Holdings of Paul Rivard
Ticker | Comapny | Latest Transaction Date | Shares Owned | Current Price ($) | Current Value ($) |
---|---|---|---|---|---|
TNFA | TNF Pharmaceuticals Inc | 2023-08-24 | 13,333 | 1.25 | 16,666 |
Holding Weightings of Paul Rivard
Paul Rivard Form 4 Trading Tracker
According to the SEC Form 4 filings, Paul Rivard has made a total of 4 transactions in TNF Pharmaceuticals Inc (TNFA) over the past 5 years, including 4 buys and 0 sells. The most-recent trade in TNF Pharmaceuticals Inc is the acquisition of 5,000 shares on August 24, 2023, which cost Paul Rivard around $166,500.
Insider Trading History of Paul Rivard
- 1
Paul Rivard Trading Performance
GuruFocus tracks the stock performance after each of Paul Rivard's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Paul Rivard is -38.04%. GuruFocus also compares Paul Rivard's trading performance to market benchmark return within the same time period. The performance of stocks bought by Paul Rivard within 3 months outperforms 1 times out of 4 transactions in total compared to the return of S&P 500 within the same period.
You can select different timeframes to see how Paul Rivard's insider trading performs compared to the benchmark.
Performance of Paul Rivard
Paul Rivard Ownership Network
Ownership Network List of Paul Rivard
Ownership Network Relation of Paul Rivard
Paul Rivard Owned Company Details
What does TNF Pharmaceuticals Inc do?
Who are the key executives at TNF Pharmaceuticals Inc?
Paul Rivard is the EVP of Operations & GC of TNF Pharmaceuticals Inc. Other key executives at TNF Pharmaceuticals Inc include director & President & Chief Med. Officer Chapman Christopher C Jr , Chief Scientific Officer Adam Kaplin , and 10 percent owner Caroline C Williams .
TNF Pharmaceuticals Inc (TNFA) Insider Trades Summary
Over the past 18 months, Paul Rivard made 2 insider transaction in TNF Pharmaceuticals Inc (TNFA) with a net purchase of 175,000.
In summary, during the past 3 months, insiders sold 0 shares of TNF Pharmaceuticals Inc (TNFA) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of TNF Pharmaceuticals Inc (TNFA) were sold and 5,833 shares were bought by its insiders, resulting in a net purchase of 5,833 shares.
TNF Pharmaceuticals Inc (TNFA)'s detailed insider trading history can be found in Insider Trading Tracker table.
TNF Pharmaceuticals Inc Insider Transactions
Paul Rivard Mailing Address
Above is the net worth, insider trading, and ownership report for Paul Rivard. You might contact Paul Rivard via mailing address: C/o Akers Biosciences, Inc., 1185 Avenue Of The Americas, 3rd Floor, New York Ny 10036.